This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miyazaki, S.
Right arrow Articles by Yamaguchi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyazaki, S.
Right arrow Articles by Yamaguchi, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2004, p. 378-383, Vol. 48, No. 2
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.2.378-383.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Pharmacodynamics of S-3578, a Novel Cephem, in Murine Lung and Systemic Infection Models

Shuichi Miyazaki,* Kenichi Okazaki, Masakatsu Tsuji, and Keizo Yamaguchi

Department of Microbiology, Toho University School of Medicine, Omori-nishi, 5-21-16, Ota-ku, Tokyo 143-8540, Japan

Received 8 April 2003/ Returned for modification 6 September 2003/ Accepted 4 October 2003

S-3578 is a novel beta-lactam with enhanced activity against drug-resistant gram-positive cocci such as methicillin-resistant Staphylococcus aureus (MRSA). We used murine penicillin-resistant Streptococcus pneumoniae lung infection and neutropenic murine systemic MRSA infection models to determine the pharmacokinetic (PK)-pharmacodynamic (PD) parameter that best correlated with efficacy. Pharmacokinetic studies revealed that the maximum concentration in serum/dose values for S-3578 and cefepime in plasma in the lung infection model were 1.21 to 1.54 and 0.97 to 1.29, respectively; those for S-3578 in plasma in the systemic infection model were 0.78 to 1.02. The area under the concentration-time curve (AUC)/dose values for S-3578 and cefepime in plasma in the lung infection model were 0.98 to 1.13 and 0.77 to 1.04, respectively, and those for S-3578 in plasma in the systemic infection model were 1.03 to 1.11. The half-lives of S-3578 and cefepime in plasma in the lung infection model were 0.29 to 0.38 and 0.29 to 0.34, respectively, and those of S-3578 in plasma in the systemic infection model were 0.40 to 0.61. The time above the MIC was the PK-PD parameter that best correlated with efficacy in the murine lung infection model (R2 = 84 and 92% for S-3578 and cefepime in plasma, respectively). There was a twofold increase in the dose of S-3578 in the systemic infection model compared to that in the pneumonia model, yet the AUCs were the same. This may be due to the different MICs for the two pathogens.

* Corresponding author. Mailing address: Department of Microbiology, Toho University School of Medicine, Omori-nishi 5-21-16, Ota-ku, Tokyo 143-8540, Japan. Phone: 81-3-3762-4151. Fax: 81-3-5493-5415. E-mail: shuichi{at}med.toho-u.ac.jp.

Antimicrobial Agents and Chemotherapy, February 2004, p. 378-383, Vol. 48, No. 2
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.2.378-383.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Tam, V. H., Schilling, A. N., Poole, K., Nikolaou, M. (2007). Mathematical modelling response of Pseudomonas aeruginosa to meropenem. J Antimicrob Chemother 60: 1302-1309 [Abstract] [Full Text]  
  • Lopez, F. E., Vincent, P. A., Zenoff, A. M., Salomon, R. A., Farias, R. N. (2007). Efficacy of microcin J25 in biomatrices and in a mouse model of Salmonella infection. J Antimicrob Chemother 59: 676-680 [Abstract] [Full Text]  
  • Tam, V. H., Schilling, A. N., Neshat, S., Poole, K., Melnick, D. A., Coyle, E. A. (2005). Optimization of Meropenem Minimum Concentration/MIC Ratio To Suppress In Vitro Resistance of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49: 4920-4927 [Abstract] [Full Text]  
  • Tam, V. H., Schilling, A. N., Nikolaou, M. (2005). Modelling time-kill studies to discern the pharmacodynamics of meropenem. J Antimicrob Chemother 55: 699-706 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»